201 related articles for article (PubMed ID: 33811019)
1. Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer.
Szabados B; Prendergast A; Jackson-Spence F; Choy J; Powles T
Eur Urol Oncol; 2021 Dec; 4(6):943-947. PubMed ID: 33811019
[TBL] [Abstract][Full Text] [Related]
2. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
3. Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
Wei XX; Werner L; Teo MY; Rosenberg JE; Koshkin VS; Grivas P; Szabados B; Morrison L; Powles T; Carril-Ajuria L; Castellano D; Velho PI; Hahn NM; McKay RR; Raggi D; Necchi A; Kanesvaran R; Alerasool P; Gaines J; Galsky M; Bellmunt J; Sonpavde G
J Urol; 2021 Feb; 205(2):414-419. PubMed ID: 32935617
[TBL] [Abstract][Full Text] [Related]
4. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
Einstein DJ; Sonpavde G
Curr Treat Options Oncol; 2019 Feb; 20(2):12. PubMed ID: 30741358
[TBL] [Abstract][Full Text] [Related]
5. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
6. Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.
Koufopoulou M; Miranda PAP; Kazmierska P; Deshpande S; Gaitonde P
Cancer Treat Rev; 2020 Sep; 89():102072. PubMed ID: 32769039
[TBL] [Abstract][Full Text] [Related]
7. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zacharis A; Grüllich C
Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
[TBL] [Abstract][Full Text] [Related]
8. First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis.
Lin CT; Su PJ; Huang SY; Wu CC; Wang HJ; Cheng YT; Luo HL; Chen CH; Liu TT; Huang CC; Su YL
J Immunother; 2022 Nov-Dec 01; 45(9):407-414. PubMed ID: 36121316
[TBL] [Abstract][Full Text] [Related]
9. [Metastatic urothelial carcinoma-guideline-based therapy and new options].
Niegisch G; von Amsberg G; Rehlinghaus M; Grunewald CM; Retz M
Urologe A; 2022 Mar; 61(3):265-272. PubMed ID: 35089362
[TBL] [Abstract][Full Text] [Related]
10. Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis.
Rizzo A; Mollica V; Santoni M; Ricci AD; Gadaleta-Caldarola G; Montironi R; Massari F
Future Oncol; 2022 Feb; 18(6):739-748. PubMed ID: 35048736
[No Abstract] [Full Text] [Related]
11. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
Feld E; Harton J; Meropol NJ; Adamson BJS; Cohen A; Parikh RB; Galsky MD; Narayan V; Christodouleas J; Vaughn DJ; Hubbard RA; Mamtani R
Eur Urol; 2019 Oct; 76(4):524-532. PubMed ID: 31362898
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis.
Martini A; Raggi D; Fallara G; Nocera L; Schultz JG; Belladelli F; Marandino L; Salonia A; Briganti A; Montorsi F; Powles T; Necchi A
Cancer Treat Rev; 2022 Mar; 104():102360. PubMed ID: 35176685
[TBL] [Abstract][Full Text] [Related]
13. Urothelial carcinoma in the era of immune checkpoint inhibitors.
Khalife N; Chahine C; Kordahi M; Felefly T; Kourie HR; Saleh K
Immunotherapy; 2021 Aug; 13(11):953-964. PubMed ID: 34184561
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward.
Bilé-Silva A; Lopez-Beltran A; Blanca A; Lopez-Rios F; Gómez-Gómez E; Cimadamore A; Montironi R; Vau N; Cheng L
Expert Opin Biol Ther; 2023 May; 23(5):407-418. PubMed ID: 37036223
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.
Raggi D; Necchi A; Giannatempo P
Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336
[TBL] [Abstract][Full Text] [Related]
16. Role of immunotherapy in bladder cancer.
Rhea LP; Mendez-Marti S; Kim D; Aragon-Ching JB
Cancer Treat Res Commun; 2021; 26():100296. PubMed ID: 33421822
[TBL] [Abstract][Full Text] [Related]
17. Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region.
Eto M; Lee JL; Chang YH; Gao S; Singh M; Gurney H
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e191-e203. PubMed ID: 35238147
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
19. Durvalumab in urothelial cancers.
Lavaud P; Hamilou Z; Loriot Y; Massard C
Expert Rev Anticancer Ther; 2018 Apr; 18(4):311-318. PubMed ID: 29486607
[TBL] [Abstract][Full Text] [Related]
20. Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
Szabados B; van Dijk N; Tang YZ; van der Heijden MS; Wimalasingham A; Gomez de Liano A; Chowdhury S; Hughes S; Rudman S; Linch M; Powles T
Eur Urol; 2018 Feb; 73(2):149-152. PubMed ID: 28917596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
